RxDoctor Payments DataLook up a doctor →

Duren Gutierrez

Psychiatric/Mental Health · Southfield, MINPI 1598003915

Payments from drug & device makers

$207,319in general payments, 2019–2025

Across 906 payments — averaging $228.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$122K
  • Alkermes, Inc.$55K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Teva Pharmaceuticals USA, Inc.$8K
  • AbbVie$8K
  • Indivior Inc.$1K
  • plus $4K from 18 others

What the payments were for

  • Consulting fees$14,0947%
  • Speaking & faculty fees$163,90979%
  • Travel & lodging$13,1146%
  • Food & beverage$16,0488%
  • Education$1540%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$207,319 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$37,690
Medicare patients
135
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate138$410,212
AristadaAripiprazole Lauroxil75$183,649
IngrezzaValbenazine Tosylate22$179,725
VraylarCariprazine Hcl136$161,340
LybalviOlanzapine/Samidorphan Malate80$120,469
Abilify MaintenaAripiprazole32$94,998
RexultiBrexpiprazole21$26,901
Clozapine213$18,237
Paliperidone ErPaliperidone46$16,611
Fluphenazine Hcl91$13,576
Aripiprazole168$8,467
Quetiapine Fumarate429$8,214
Fluphenazine Decanoate67$7,041
Lurasidone Hcl26$6,164
Benztropine Mesylate411$5,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$121,937$410,212138 claims
Alkermes, Inc.Aristada, Lybalvi$55,445$304,118155 claims
Neurocrine Biosciences, Inc.Ingrezza$891$179,72522 claims
AbbVieVraylar$7,648$161,340136 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$657$121,89953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →